Business
Replimune Appoints Christy Oliger to its Board of Directors
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates
About this update from Replimune Group, Inc.
[{"type":"text","content":"WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to welcome Christy to Replimune’s Board of Directors,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our board as we advance our leading pipeline of oncolytic immunotherapies to market.” Previously Ms. Oliger was Senior Vice President of the Oncology Business Unit at Genentech responsible for all commercial activities in the US. Ms. Oliger spent two decades with Genentech, holding a number of leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio Planning and Vice President, Hematology Marketing and Sales. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger currently serves as a member of the board of Karyopharm Therapeutics Inc., Reata Pharmaceuticals, Inc. and Sierra Oncology, Inc. Ms. Oliger holds a bachelor’s degree in Economics from the University of California at Santa Barbara. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune inten...